Development and Validation a Nomogram and Prognosis of Chemotherapy for Evaluation in Giant-cell Lung Carcinoma With Metastases: A Propensity Score Matching Analysis

Abstract Background and Objectives: Whether chemotherapy couldimprove prognosis for giant-celllung carcinoma with metastases remains controversial. The present study aimed to determine the significanceof chemotherapy in patients with metastases giant-cell Lung carcinoma, and to develop a nomogram to predict its outcomes.Methods:Data of 566 patients from the Surveillance, Epidemiology, and End Results(SEER) database were analyzed; 346 matched patients were divided into a chemotherapy group and non-chemotherapy group, respectively, using the propensity scorematching method. Univariate and multivariate analyses were performed to determine theprognostic factors of giant-celllung carcinoma, and subgroup analysis was performed according tothe site of metastases. While a visual nomogram wasestablished to judge the prognosis.Results: With the median follow-up of 20.5 months, The 3-yearsurvival rates were 20.2% in the chemotherapy set and 16.7% in the non-chemotherapy set (P=0.006).Chemotherapy did improve the Giant-cell Lung Carcinoma survival rates in patients with metastases(HR = 0.490, 95% CI = 0.358–0.669, P<0.001). In subgroup analysis, radiotherapy did not improved the Giant-cell Lung Carcinoma survival rates in patients with metastases(HR = 0.951, 95% CI = 0.690-1.311, P = 0.758, Table 2). Chemotherapy improved the CSS in patients with lung metastases (HR = 0.090, 95% CI = 0.017-0.470, P =0.004).In addition, chemotherapy improved the CSS in patients with brain metastases (HR = 0.117, 95% CI = 0.014-0.955, P =0.045). Compared with bone metastasis, liver metastasis and metastasis of more than 2 sites, the effect of chemotherapy is not obvious.Furthermore, our nomogram could predict the probability of surviving to the median survival time of the population with a c-index of 0.768.Conclusion:The benefit of chemotherapy in giant-celllung carcinoma with metastases patients was obviously different, andthe recommendation of chemotherapy for this population should be individualized. chemotherapy shouldbe considered for patients with only lungmetastasis or brain metastasis, but chemotherapy could be avoided in those with other site metastases or multiple metastases.We developed the first competing risk nomogram to predict the risk of GCLC patients, which performed well in the evaluation and might be helpful for individualized screening.

Download Full-text

A rare case of giant cell lung carcinoma with intracardiac extension via the pulmonary vein and thrombus formation

Journal of Surgical Case Reports ◽

10.1093/jscr/rjy144 ◽

2018 ◽

Vol 2018 (6) ◽

Author(s):

Vasileios Leivaditis ◽

Efstatios Koletsis ◽

Konstantinos Spiliotopoulos ◽

Konstantinos Grapatsas ◽

Vasiliki Tzelepi ◽

...

Keyword(s):

Giant Cell ◽

Pulmonary Vein ◽

Lung Carcinoma ◽

Rare Case ◽

Thrombus Formation ◽

Cell Lung Carcinoma ◽

Intracardiac Extension

Download Full-text

CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma

Biomarkers in Medicine ◽

10.2217/bmm.13.55 ◽

2013 ◽

Vol 7 (4) ◽

pp. 591-599 ◽

Cited By ~ 5

Author(s):

Lei Liu ◽

Bin Liu ◽

Li-li Zhu ◽

Yu Li

Keyword(s):

Squamous Cell Carcinoma ◽

Tumor Marker ◽

Cell Carcinoma ◽

Squamous Cell ◽

Lung Carcinoma ◽

Serum Tumor Marker ◽

Squamous Cell Lung Carcinoma ◽

Cell Lung Carcinoma ◽

Oropharynx Squamous Cell Carcinoma

Download Full-text

Antisense Tiam1 Down-Regulates the Invasiveness of 95D Cells in Vitro

Acta Biochimica et Biophysica Sinica ◽

10.1093/abbs/36.8.537 ◽

2004 ◽

Vol 36 (8) ◽

pp. 537-540 ◽

Cited By ~ 26

Author(s):

Min Hou ◽

Li Tan ◽

Xia Wang ◽

Yun-Song Zhu

Keyword(s):

Giant Cell ◽

Lung Carcinoma ◽

Expression Level ◽

Nucleotide Exchange ◽

Invasion And Metastasis ◽

Cell Lung Carcinoma ◽

Lung Carcinoma Cells ◽

T Lymphoma ◽

In Vitro Invasiveness

Abstract As a specific guanine nucleotide exchange factor of Rac1, Tiam1 (T-lymphoma invasion and metastasis inducing protein 1) is involved in a number of cellular events, such as cytoskeleton reorganization, cell adhesion, and cell migration. Since Tiam1 was implicated in the invasion and metastasis of T-lymphoma cells and breast tumor cells, we compared the expression level of Tiam1 in two human giant-cell lung carcinoma cell strains with high or low metastasis potential, and found that Tiam1 expression level in high-metastatic 95D cells was higher than that in low-metastatic 95C cells. To further confirm the role of Tiam1 in invasion and metastasis, we constructed the antisense Tiam1 expression plasmid (pcDNA3-anti-Tiam1), which was transfected into 95D cells. A stable transfected clone with decreased Tiam1 expression was screened and selected for further research. Transwell assay showed that down-regulation of endogenous Tiam1 by anti-Tiam1 can reduce the in vitro invasiveness of 95D cells. Our results suggested that Tiam1 signaling contributed to the invasion and metastasis of the human giant-cell lung carcinoma cells.

Download Full-text

Sarcoligo: Impact of local ablative treatment of oligometastatic sarcomas on overall survival.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.10042 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 10042-10042

Author(s):

Juliette Thariat ◽

Laurence Moureau-Zabotto ◽

Nicolas Penel ◽

Antoine Italiano ◽

Jacques-Olivier Bay ◽

...

Keyword(s):

Overall Survival ◽

Lung Metastases ◽

Univariate Analysis ◽

Survival Rates ◽

Locoregional Treatment ◽

Metastatic Sites ◽

The Impact

10042 Background: 40-50% of sarcomas become metastatic. Median survival of metastatic patients has improved over time. The probably multifactorial reasons for such improvement are not fully clear. Noteworthy, for patients with a controlled primary and a limited number of lung metastases, complete resection of their metastases yields survival rates of up to 40% at three years. Advances in surgery, radiotherapy and radiofrequency have fostered the use of local treatments for various metastatic sites (lung, liver, spine...). Methods: A multicentric retrospective study of the Groupe Sarcome Francais (GSF-GETO); approved by the nationally-review board and ethical committee, was conducted to assess the impact of local ablative treatment on overall survival. Patients who had had oligometastases (any site, 1-5 synchronous metastases) at diagnostic or during the course of disease between 2000 and 2010 were included. Results: Median age of the 243 oligometastatic sarcoma patients was 53 years-old (11-86). Patients had grade I, II and III in 7.5%, 29.6% and 63.3% of cases, respectively with various histologies. 69% of patients underwent local ablative treatment of metastases. Median follow-up was 59 months (4-212) for living patients. Median overall survival was 51 months (1-348). On univariate analysis, grade, histology, absence of chemotherapy, local ablative treatment (surgery, irradiation, radiofrequency or chemoembolisation) correlated with survival but not age or site of oligometastasis. On multivariate analyses, grade (hazard ratio HR 0.12 [CI95 0.3-0.6]) and local ablative treatment (HR 3.8 [CI95 2.1-7.1]) remained significant. Conclusions: Local ablative treatment of metastases is associated with better survival in sarcoma patients with oligometastatic disease. The role of the locoregional treatment of metastases and its impact on quality of life should be assessed prospectively.

Download Full-text